Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus (TIDM). Mortality is predominantly related to the occurrence of cerebral oedema; only a minority of deaths in DKA are attributed to other causes. Cerebral oedema occurs in about 0.3–1% of all episodes of DKA, and its aetiology, pathophysiology, and ideal method of treatment are poorly understood. There is debate as to whether physicians treating DKA can prevent or predict the occurrence of cerebral oedema, and the appropriate site(s) for children with DKA to be managed. There is agreement that prevention of DKA and reduction of its incidence should be a goal in managing children with diabetes.

DEFINITION OF DIABETIC KETOACIDOSIS

Diabetic ketoacidosis (DKA) is caused by a decrease in effective circulating insulin associated with increases in counter regulatory hormones including glucagon, catecholamines, cortisol, and growth hormone. This leads to increased glucose production by the liver and kidney and impaired peripheral glucose utilisation with resultant hyperglycaemia, and hyperosmolality. Increased lipolysis, with ketone body (beta-hydroxybutyrate, acetoacetate) production causes ketonaemia and metabolic acidosis. Hyperglycaemia and acidosis result in osmotic diuresis, dehydration, and obligate loss of electrolytes. The biochemical criteria for the diagnosis of DKA include hyperglycaemia (blood glucose >11 mmol/l (~200 mg/dl)) with a venous pH <7.3 and/or bicarbonate <15 mmol/l. There is associated glycosuria, ketonuria, and ketonaemia. Rarely, young or partially treated children as well as pregnant adolescents may present with near normal glucose values ("euglycaemic ketoacidosis").

DKA is generally categorised by the severity of the acidosis; varying from mild (venous pH <7.30, bicarbonate concentration <15 mmol/l), to moderate (pH <7.2, bicarbonate <10), to severe (pH <7.1, bicarbonate <5).

FREQUENCY OF DKA

At disease onset

There is wide geographic variation in the frequency of DKA at diabetes onset and rates correlate inversely with regional incidence of TIDM. Reported frequencies range between 15% and 67% in Europe and North America and may be more common in developing countries (A). In Canada and Europe, hospitalisation rates for DKA in established and new patients with TIDM have remained stable at about 10 per 100 000 children over the past 20 years, but severity may be decreasing (B).

DKA at onset of TIDM is more common in younger children (<4 years of age), children without a first degree relative with TIDM, and those from families of lower socioeconomic status (A). High dose glucocorticoids, atypical antipsychotics, diazoxide, and
some immunosuppressive drugs have been reported to precipitate DKA in individuals not previously diagnosed with TIDM (B).10 11

In children with established TIDM
The risk of DKA in established TIDM is 1–10% per patient per year (A).12–15 Risk is increased in children with poor metabolic control or previous episodes of DKA; peripubertal and adolescent girls; children with psychiatric disorders, including those with eating disorders; and those with difficult family circumstances, including lower socioeconomic status and lack of appropriate health insurance.16 Inappropriate interruption of insulin pump therapy also leads to DKA.17 18

Children whose insulin is administered by a responsible adult rarely have episodes of DKA (C),17 and 75% of episodes of DKA beyond diagnosis are probably associated with insulin omission or treatment error.17 18 The remainder are due to inadequate insulin therapy during intercurrent illness (B).19–20

MORBIDITY AND MORTALITY OF DKA IN CHILDREN
Reported mortality rates from DKA in national population based studies are reasonably constant: 0.15% (C) (USA),21 0.18% (C) (Canada),22 0.25% (C) (Canada),22 and 0.31% (B) (UK).23 In places with less developed medical facilities, the risk of dying from DKA is greater, and children may die before receiving treatment.24

Cerebral oedema accounts for 57–87% of all DKA deaths.25 26 The incidence of cerebral oedema has been fairly consistent between national population based studies: 0.46% (C) (Canada),22 0.68% (B) (UK),24 and 0.87% (B) (USA).25 Single centre studies often report higher frequencies because of ascertainment bias arising from secondary referral patterns: 1.1% (C) (USA)26 to 4.6% (USA).27

Reported mortality rates from cerebral oedema, in population based studies are 21% (C),25 25% (C),22 and 24% (B).28 Significant morbidity is evident in 10% (C),22 21% (B),25 and 26% (B)4 of survivors. However, some individual centres have reported markedly lower mortality and serious morbidity following DKA and cerebral oedema [(B) (USA),29 C (USA)].30

Other possible causes of mortality and morbidity include hypokalaemia, hyperkalaemia, hypoglycaemia, other CNS complications; haematoma (C),30 thrombosis (C),31 sepsis, and infections (including rhinocerebral mucormycosis) (C),32 aspiration pneumonia, pulmonary oedema (C),33 adult respiratory distress syndrome (ARDS) (C),34 pneumomediastinum and subcutaneous emphysema (C),35 and rhabdomyolysis (C).36 Late sequelae relate to cerebral oedema and other CNS complications; these include hypothalamic/pituitary insufficiency,17 18 isolated growth hormone deficiency,29 and combined GH and TSH deficiency.40

CEREBRAL OEDEMA
Presentation
Cerebral oedema typically occurs 4–12 hours after treatment is activated,33 41 but can be present before treatment has begun [(B),24 (C)41 42 (B)42], or may develop any time during treatment for DKA. Symptoms and signs of cerebral oedema are variable and include onset of headache, gradual decrease or deterioration in level of consciousness, inappropriate slowing of the pulse rate, and an increase in blood pressure (C).34 43

Pathophysiology
In vitro experiments and studies in animals and in humans presenting with cerebral oedema due to other causes (for example, trauma, stroke) suggest that the aetiopathological mechanisms may be complex. A number of mechanisms have been proposed including the role of cerebral ischaemia/hypoxia and the generation of various inflammatory mediators,44–47 increased cerebral blood flow,44 45 and disruption of cell membrane ion transport46 50 and aquaporin channels.51 The generation of intracellular organic osmolytes (myoinositol, taurine) and subsequent cellular osmotic imbalance has also been implicated.52 Preliminary imaging studies in children with DKA using ultrasound, computed tomography or magnetic resonance imaging indicate that some degree of cerebral oedema may be present even in patients without clinical evidence of raised intracranial pressure.53–56

Demographics
Various demographic factors have been associated with an increased risk of cerebral oedema including: presentation with new onset TIDM (B),25 (C),44 younger age (C),44 and longer duration of symptoms (C).25 These associations may be a consequence of the greater likelihood of presenting with severe DKA (C).25

Risk factors
Several potential risk factors, at diagnosis or during treatment, have been identified through epidemiological studies.

- There is evidence that an attenuated rise in measured serum sodium concentrations during therapy for DKA may be associated with increased risk of cerebral oedema (C).25 57 58 There is little evidence, however, to show associations between the volume or sodium content of intravenous fluids or rate of change in serum glucose and risk for cerebral oedema (C).25–27 58 59 Therefore, it is unclear whether the association between sodium change and cerebral oedema reflects variations in fluid administration, or the effects of cerebral injury on renal salt handling.

- There is some evidence to support an association between severity of acidosis and risk of cerebral oedema (C).60 There is also evidence for an association between bicarbonate treatment for correction of acidosis and increased risk of cerebral oedema (C).25 61

- Greater hypocapnia at presentation of DKA, after adjusting for the degree of acidosis, has been associated with cerebral oedema in two studies (C).25–27 This association correlates well with the observed detrimental effects of hypocapnia in other conditions (B).62

- Increased serum urea nitrogen at presentation of DKA is associated with increased risk of cerebral oedema (C),25 and this association may reflect greater dehydration in these patients.

Most studies show no association between the degree of hyperglycaemia at presentation of DKA with risk of cerebral oedema after correcting for other covariates (C).25–27

MANAGEMENT OF DKA
General issues
Children with ketosis and hyperglycaemia without vomiting or severe dehydration can be managed at home or in an outpatient health care setting (for example, emergency ward or units with similar facilities) but the level of care needs to be re-evaluated frequently and supervised by an experienced diabetes team [(C)31–34, (E)].

A specialist/consultant paediatrician with training and expertise in the management of DKA should direct inpatient management. The child should also be cared for in a unit which has: experienced nursing staff trained in monitoring and management; clear written guidelines; and access to laboratories for frequent evaluation of biochemical variables.
Children with signs of severe DKA (long duration of symptoms, compromised circulation, or depressed level of consciousness) or those who are at increased risk for cerebral oedema (including <5 years of age, new onset) should be considered immediately for treatment in an intensive care unit (paediatric if available) or in a children’s ward specialising in diabetes care with equivalent resources and supervision [(C) (E)]. If transfer by ambulance to another unit is required, caution should be exercised in use of sedatives and antiemetics.

Monitoring

There should be documentation of hour by hour neurological observations, intravenous and oral medication, fluids, and laboratory results during the entire treatment period (E). Monitoring should include the following:

- Hourly heart rate, respiratory rate, blood pressure.
- Hourly (or more frequent) accurate fluid input and output (where there is impaired level of consciousness, urinary catheterisation may be necessary).
- In severe DKA, ECG monitoring may be helpful to assess T-waves for evidence of hyperkalaemia/hypokalaemia.
- Capillary blood glucose should be monitored hourly (but must be cross checked against laboratory venous glucose as capillary methods may be inaccurate in the presence of poor peripheral circulation and acidosis).
- Laboratory tests: electrolytes, urea, haematocrit, blood glucose, and blood gases should be repeated 2–4 hourly. (However, electrolytes should be monitored hourly as clinically indicated in the more severe cases.) An increased WBC may be due to stress and cannot be taken as a sign of infection.
- Hourly or more frequent neurological observations for warning signs and symptoms of cerebral oedema:
  - Headache
  - Inappropriate slowing of heart rate
  - Recurrence of vomiting
  - Change in neurological status (restlessness, irritability, increased drowsiness, incontinence) or specific neurological signs (for example, cranial nerve palsies, pupillary response)
  - Rising blood pressure
  - Decreased oxygen saturation.

Those monitoring should be instructed to alert the physician of any of these manifestations, as it may be difficult to clinically discriminate cerebral oedema from other causes of altered mental status.

Fluids and salt (table 1)

The high effective osmolality of the extracellular fluid (ECF) compartment results in a shift of water from the intracellular fluid compartment (ICF) to the ECF. Studies performed in adults with TIDM in whom insulin therapy was withheld have shown fluid deficits of around 5 litres together with approximately 20% loss of total body sodium and potassium. At the time of presentation, patients are ECF contracted and clinical estimates of the deficit are usually in the range of 7–10%, although these can be subjective and may overestimate the problem. Shock with haemodynamic compromise is a rare event in DKA. The serum sodium measurement is an unreliable measure of the degree of ECF contraction due to the dilutional effect of fluid shift. The effective osmolality (2 [Na + K] + glucose) at the time of presentation is frequently in the range of 300–350 mmosm/l. Increased serum urea nitrogen and haematocrit may be useful markers of severe ECF contraction.

The onset of dehydration is associated with a reduction in glomerular filtration rate (GFR), which results in decreased glucose and ketone clearance from the blood. Studies in humans have shown that intravenous fluid administration alone results in substantial falls in blood glucose levels because of an increase in GFR. The objectives of fluid and sodium replacement therapy in DKA are: (a) restoration of circulating volume, (b) replacement of sodium and the ECF and ICF deficit of water, (c) the restoration of GFR with enhanced clearance of glucose and ketones from the blood, and (d) the avoidance of cerebral oedema.

Both animal and human studies have shown that intracranial pressure (ICP) rises as intravenous fluids are administered. There are also animal models of DKA which show that the use of hypotonic fluids, compared to isotonic, is associated with greater rises in ICP. Although there are no category A studies that show superiority of any fluid regimen over another, there are category C data that suggest that rapid fluid replacement with hypotonic fluid is associated with an increased risk of cerebral oedema (see section on risk factors above). There are both adult (category A) and paediatric (level B) studies which show that a less rapid fluid deficit correction with isotonic or near-isotonic solutions results in earlier reversal of acidosis. However, the use of large amounts of 0.9% saline has also been associated with the development of hyperchloremic metabolic acidosis.

There are no data to support the use of colloids in preference to crystalloids in the treatment of DKA. There are also no data to support the use of solutions more dilute than 0.45% NaCl; the use of these solutions, which contain a large amount of electrolyte free water, is likely to lead to a rapid osmolar change and movement of fluid into the ICF compartment.

Insulin (table 2)

Although rehydration alone causes some decrease in blood glucose concentration, insulin therapy is essential to normalise the blood glucose concentration and to suppress lipolysis and ketogenesis. Although different routes (subcutaneous, intramuscular, intravenous) and doses have been used, extensive evidence indicates that “low dose” intravenous insulin administration should be the standard of care.

Physiological studies indicate that intravenous insulin at a dose of 0.1 unit/kg/hour, which achieves steady state plasma insulin levels of around 100–200 U/ml within 60 minutes, is effective. Such plasma insulin levels are able to offset insulin resistance and, in most circumstances, inhibit lipolysis and ketogenesis; exerting maximal or near maximal effects on suppression of glucose production and stimulated peripheral glucose uptake. The resolution of acidemia invariably takes longer than normalisation of blood glucose concentrations.

Potassium (table 3)

Adults with DKA have total body potassium deficits of the order of 3–6 mmol/kg; data in children are sparse. The major loss of potassium is from the intracellular pool as a result of hypertonicity, insulin deficiency, and buffering of hydrogen ions within the cell. Serum potassium levels at the time of presentation may be normal, increased or decreased: hypokalaemia at presentation may be related to prolonged duration of disease, whereas hyperkalaemia primarily results from reduced renal function. Administration of insulin and the correction of acidosis will drive potassium back into the cells, decreasing serum levels.

Phosphate (table 3)

Depletion of intracellular phosphate occurs and phosphate is lost as a result of osmotic diuresis. In adults, deficits are in
Diabetic ketoacidosis in children and adolescents

Table 1 Water and salt replacement in DKA

- Water and salt deficits must be replaced. Intravenous or oral fluids that may have been given before the child presents for treatment and prior to assessment should be factored into calculation of deficit and repair. (A)
- Initial intravenous fluid administration and, if needed, volume expansion, should begin immediately with an isotonic solution (0.9% saline or balanced salt solutions such as Ringer’s lactate). The volume rate of administration depends on circulatory status and, where it is clinically indicated, the volume is typically 10–20 ml/kg over 1–2 hours, repeated if necessary. (B)
- Use crystalloid and not colloid. (C)
- Subsequent fluid management should be with a solution with a tonicity equal to or greater than 0.45% saline. (C)
  - This can be achieved by administering 0.9% saline or, balanced salt solution (Ringer’s lactate or 0.45% saline with added potassium). (B)
  - Rate of intravenous fluid should be calculated to rehydrate evenly over at least 48 h. (B)
- In addition to clinical assessment of dehydration, calculation of effective osmolality may be valuable to guide fluid and electrolyte therapy. (B)
- As the severity of dehydration may be difficult to determine and can be overestimated, infuse fluid each day at a rate rarely in excess of 1.5–2 times the usual daily requirement based on age, weight, or body surface area. Urinary losses should not be added to the calculation of replacement fluids. (B)

Acidosis (table 3)
Even severe acidosis is reversible by fluid and insulin replacement. Administration of insulin stops further ketoacidosis and spontaneous correction of acidaemia. Also, treatment of hypovolaemia will improve decreased tissue perfusion and renal function, thus increasing the excretion of organic acids (see “Fluids and salt” above) and reversing any lactic acidaemia, which may account for 25% of the acidaemia.

Acidosis caused by bicarbonate will result in hypokalaemia, may accentuate sodium load, and contribute to serum hypertonicity. In addition, alkali therapy may increase hepatic ketone production, thus slowing the rate of recovery from the ketoacidosis.

Table 2 Insulin therapy for DKA

- Correction of insulin deficiency: (A)
  - Dose: 0.1 units/kg/hour (A)
  - Route of administration: intravenous (A)
- The dose of insulin should remain at 0.1 U/kg/hour at least until resolution of ketoadiasis (pH <7.30, HCO3 -15 mmol/l and/or closure of anion gap). To prevent an unduly rapid decrease in plasma glucose concentration and possible development of hypoglycaemia, glucose should be added to the intravenous fluid when the plasma glucose falls to ~14–17 mmol/l (250–300 mg/dl). (B)
- There may be circumstances where the insulin dose may be safely reduced earlier, but the criteria have not been defined. (B)
- If biochemical parameters of ketoadiasis (pH, anion gap) do not improve, reassess the patient, review insulin therapy, and consider other possible causes of impaired response to insulin; e.g. infection, errors in insulin preparation, adhesion of insulin to tubing with very dilute solutions. (E)
- There is evidence that an intravenous bolus of insulin is not necessary (C). However, a bolus may be used at the start of insulin therapy, particularly if insulin treatment has been delayed. (E)
- In unusual circumstances where intravenous administration is not possible, the intramuscular or subcutaneous route of insulin administration has been used effectively (C). However, poor perfusion will impair absorption of insulin. (E)

There are potential arguments against the use of bicarbonate. Of concern is that bicarbonate therapy may paradoxically cause hyperkalaemia (arterial pH <6.9) in whom decreased cardiac contractility and peripheral vasodilatation can further impair tissue perfusion, and patients with potentially life threatening hyperkalaemia.

Table 1 Water and salt replacement in DKA

<table>
<thead>
<tr>
<th>Water and salt replacement in DKA</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Water and salt deficits must be replaced. Intravenous or oral fluids that may have been given before the child presents for treatment and prior to assessment should be factored into calculation of deficit and repair. (A)</td>
</tr>
<tr>
<td>• Initial intravenous fluid administration and, if needed, volume expansion, should begin immediately with an isotonic solution (0.9% saline or balanced salt solutions such as Ringer’s lactate). The volume rate of administration depends on circulatory status and, where it is clinically indicated, the volume is typically 10–20 ml/kg over 1–2 hours, repeated if necessary. (B)</td>
</tr>
<tr>
<td>• Use crystalloid and not colloid. (C)</td>
</tr>
<tr>
<td>• Subsequent fluid management should be with a solution with a tonicity equal to or greater than 0.45% saline. (C)</td>
</tr>
<tr>
<td>- This can be achieved by administering 0.9% saline or, balanced salt solution (Ringer’s lactate or 0.45% saline with added potassium). (B)</td>
</tr>
<tr>
<td>- Rate of intravenous fluid should be calculated to rehydrate evenly over at least 48 h. (B)</td>
</tr>
<tr>
<td>• In addition to clinical assessment of dehydration, calculation of effective osmolality may be valuable to guide fluid and electrolyte therapy. (B)</td>
</tr>
<tr>
<td>• As the severity of dehydration may be difficult to determine and can be overestimated, infuse fluid each day at a rate rarely in excess of 1.5–2 times the usual daily requirement based on age, weight, or body surface area. Urinary losses should not be added to the calculation of replacement fluids. (B)</td>
</tr>
</tbody>
</table>

Acidosis (table 3)
Even severe acidosis is reversible by fluid and insulin replacement. Administration of insulin stops further ketoacidosis and allows excess ketoadics to be metabolised. The metabolism of keto-anion results in the regeneration of bicarbonate (HCO3-) and spontaneous correction of acidaemia. Also, treatment of hypovolaemia will improve decreased tissue perfusion and renal function, thus increasing the excretion of organic acids (see “Fluids and salt” above) and reversing any lactic acidaemia, which may account for 25% of the acidaemia.

In DKA there is an increased anion gap. The major retained anion is beta-hydroxybutyrate (β-OHB) and acetocacetate.

Anion gap = [Na+] – ([Cl-] + [HCO3-])
 normally 12 ± 2 mmol/l

The indications for bicarbonate therapy in DKA are unclear. Several controlled trials of sodium bicarbonate in small numbers of children and adults (B, C) have been unable to show clinical benefit or any important difference in the rate of rise in the plasma bicarbonate concentration (C). There are potential arguments against the use of bicarbonate. Of concern is that bicarbonate therapy may paradoxically cause hyperkalaemia (arterial pH <6.9) in whom decreased cardiac contractility and peripheral vasodilatation can further impair tissue perfusion, and patients with potentially life threatening hyperkalaemia.

Table 2 Insulin therapy for DKA

<table>
<thead>
<tr>
<th>Insulin therapy for DKA</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Correction of insulin deficiency: (A)</td>
</tr>
<tr>
<td>- Dose: 0.1 units/kg/hour (A)</td>
</tr>
<tr>
<td>- Route of administration: intravenous (A)</td>
</tr>
<tr>
<td>- The dose of insulin should remain at 0.1 U/kg/hour at least until resolution of ketoadiasis (pH &lt;7.30, HCO3 -15 mmol/l and/or closure of anion gap). To prevent an unduly rapid decrease in plasma glucose concentration and possible development of hypoglycaemia, glucose should be added to the intravenous fluid when the plasma glucose falls to ~14–17 mmol/l (250–300 mg/dl). (B)</td>
</tr>
<tr>
<td>- There may be circumstances where the insulin dose may be safely reduced earlier, but the criteria have not been defined. (B)</td>
</tr>
<tr>
<td>- If biochemical parameters of ketoadiasis (pH, anion gap) do not improve, reassess the patient, review insulin therapy, and consider other possible causes of impaired response to insulin; e.g. infection, errors in insulin preparation, adhesion of insulin to tubing with very dilute solutions. (E)</td>
</tr>
<tr>
<td>- There is evidence that an intravenous bolus of insulin is not necessary (C). However, a bolus may be used at the start of insulin therapy, particularly if insulin treatment has been delayed. (E)</td>
</tr>
<tr>
<td>- In unusual circumstances where intravenous administration is not possible, the intramuscular or subcutaneous route of insulin administration has been used effectively (C). However, poor perfusion will impair absorption of insulin. (E)</td>
</tr>
</tbody>
</table>
Table 3  Potassium, phosphate, and acid base management

<table>
<thead>
<tr>
<th>Potassium</th>
<th>Phosphate</th>
<th>Acid base</th>
</tr>
</thead>
<tbody>
<tr>
<td>Replacement is required. (A)</td>
<td>There is no evidence that replacement has clinical benefit. (A) Severe hypophosphataemia should be treated. (C)</td>
<td>Other acute resuscitation protocols no longer recommend bicarbonate administration unless the acidosis is “profound” and likely to affect the action of adrenaline/epinephrine during resuscitation (A)</td>
</tr>
<tr>
<td>Replacement therapy should be based on serum potassium measurements. (B)</td>
<td>Potassium phosphate salts may be used as an alternative to or combined with potassium chloride/acetate. (C)</td>
<td>Fluid and insulin replacement without bicarbonate administration corrects ketonemia. (A)</td>
</tr>
<tr>
<td>Start potassium replacement immediately if the patient is hypokalaemic; otherwise, start potassium concurrent with starting insulin therapy. If the patient is hyperkalaemic, defer potassium until urine output is documented. (B)</td>
<td>Administration of phosphate may induce hypocalcaemia. (C)</td>
<td>Data show that treatment with bicarbonate confers no clinical benefit. (B)</td>
</tr>
<tr>
<td>Starting potassium concentration in the infusate should be 40 mmol/l (B) and potassium replacement should continue throughout intravenous fluid therapy. (B)</td>
<td>Repair fluids containing various buffering agents (bicarbonate, acetate, lactate) have been used (C). The efficacy and safety of these agents have not been established. (C)</td>
<td>Repair fluids containing various buffering agents (bicarbonate, acetate, lactate) have been used (C). The efficacy and safety of these agents have not been established. (C)</td>
</tr>
</tbody>
</table>

There are no data regarding glucocorticoid use in DKA related cerebral oedema.}

PREVENTION OF DKA

Before diagnosis

Earlier diagnosis through genetic and immunological screening of high risk children such as in the recent DPT-1 study,106 decrease DKA incidence at diabetes onset (A).106 High levels of awareness related to the existence of other members of families with TIDM also reduces risk of DKA. A school and physician awareness campaign, targeted at 6–14 year olds, reduced rates of DKA from 78% to almost 0% over a six year period. (B).110 Increased public awareness of signs and symptoms of diabetes should lead to earlier diagnosis, particularly in children under the age of 5 years where checking urine or blood for glucose may prevent misdiagnosis (E). Although such strategies are intuitively obvious, programmes to decrease DKA at onset need to be designed and evaluated in diverse populations and age groups.

Beyond diagnosis

Studies of the effects of comprehensive diabetes programmes and telephone helplines report a reduction in the rates of DKA from 15–60 to 5–9/100 patient-years (B).110 112 In patients on continuous subcutaneous insulin pumps, episodes of DKA can be reduced with the introduction of educational algorithms (E). Therefore, it is likely that episodes of DKA after diagnosis could be reduced if all children with diabetes receive comprehensive diabetes health care and education, and have access to a 24 hour diabetes telephone helpline (B).112 The value of home measurement of betahydroxybutyrate as a mechanism for earlier diagnosis and thus prevention of hospitalisation needs to be assessed. Multiple episodes of recurrent DKA are more problematic: in a recent UK study 4.8% of patients accounted for 22.5% of all episodes over a three year period.24 Insulin omission has been identified as the major factor in most of these cases and may be confirmed by finding low free insulin levels on admission (C).113 There is no evidence that mental health interventions alone can impact on the frequency of DKA in these children (B),114 117 118 but insulin omission can be prevented by sequential schemes providing education, psychosocial evaluation, and treatment combined with adult supervision of insulin administration (B).17 When responsible adults administer insulin, a tenfold reduction in episodes of DKA has been reported (B).13

KEY ISSUES FOR FUTURE INVESTIGATION

Prevention

- Efficacy and cost effectiveness of strategies to reduce DKA incidence. Frequency and evaluation of ketoacidosis in type 2 diabetes mellitus.

Management

- Improved assessment of dehydration. Systematic evaluation of rehydration solutions, such as those containing bicarbonate, acetate, lactate, and phosphate. Use of lower doses of insulin in younger children. Criteria for reducing dose of insulin during treatment of DKA need to be clarified. Need for bicarbonate therapy in those with pH <6.9 and the very young.

Cerebral oedema

- Meta-analysis of existing epidemiological studies to identify factors related to increased risk in infants, and the newly diagnosed. Monitoring of DKA and earlier detection of signs of cerebral oedema. Efficacy of hypertonic saline versus mannitol.

ACKNOWLEDGEMENTS

The LWPES and ESPE gratefully acknowledge Aventis Pharmaceuticals, Novo Nordisk, and The Society for Endocrinology for their support of the consensus conference, Sien Renstad of Senser for organising the conference, and Emily Knight and Kathy Wypychowski for assistance with preparing the consensus statement.

Authors’ affiliations

D B Dunger, C L Acerini, T P A Danne, R Hanas, M O Savage, R C Tasker, Joseph I Wolfsdorf, Lawson Wilkins Pediatric Endocrine Disease (LWPES)

Participants: Carlo L Acerini, Cambridge UK; Dorothy J Becker, Pittsburgh, USA; Desmond Bohn, Toronto, Canada; Stuart J Brink, Waltham, USA; Francesca Ciurelli, Chieti, Italy; Maria Craig, Kogarah, Australia; Gisela Dahlquist, Umea, Sweden; Denis Daneman, Toronto, Canada; Thomas Danne, Hanover, Germany; David B Dunger, Cambridge, UK; Julie A Edge, Oxford, UK, Ima Fiodralisli, Greenville, USA; Nicole S Glaser, Sacramento, USA; John Gregory, Cardiff, UK; Mitchell Halperin, Toronto, Canada; Ragnar Hanas, Udelavalla, Sweden; Glen Harris, Greeniville, USA; Money W Hammond, Houston, USA; Ray L Hintz, Stanford, USA; Carol Inwood, Cardiff, UK; Chris Kelnar, Edinburgh, UK; Wieland Kiess, Leipzig, Germany; Mikael Knip, Helsinki, Finland; Elliot J Krane, Stanford, USA; Nathan Kuppermann, Sacramento, USA; Sarah Muirhead Lawrence, Ottawa, Canada; Lynne Levitsky, Boston, USA; Marc Maes, Brussels, Belgium; Henrik Mortensen, Glostrup, Denmark; Andrew Muir, Augusta, USA; Andreas Neu, Tubingen, Germany; Jose Ramet, Brussels, Belgium; Robert Rapaport, New York, USA; Arleta Rewers, Denver, USA; Marian J Rewers, Denver, USA; Arian L Rosenblum, Gainesville, USA; Martin O Savage, London, UK; Mark A Sperling, Pittsburgh, USA; Peter Swift, Leicester, UK; William V Tamborlane, New Haven, USA; Robert C Tasker, Cambridge, USA; Nadia Tubiana-Rui, Paris, France; Maurizio Vanelli, Parma, Italy; Diane K Wherrett, Toronto, Canada; Neil H White, St Louis, USA; Joseph I Wolfsdorf, Boston, USA.

APPENDIX

Table A1 presents the ADA evidence grading system for clinical practice recommendations.
Table A1  ADA evidence grading system for clinical practice recommendations*

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Clear evidence from well conducted, generalisable, randomised controlled trials that are adequately powered, including:</td>
</tr>
<tr>
<td></td>
<td>• Multicentre trial</td>
</tr>
<tr>
<td></td>
<td>• Meta-analysis incorporating quality ratings</td>
</tr>
<tr>
<td></td>
<td>• Compelling non-experimental evidence (i.e. &quot;all or none&quot; rule) developed by the Centre for Evidence Based Medicine at Oxford</td>
</tr>
<tr>
<td>B</td>
<td>Supportive evidence from well conducted randomised controlled trials that are adequately powered, including:</td>
</tr>
<tr>
<td></td>
<td>• Well conducted trials at one or more institutions</td>
</tr>
<tr>
<td></td>
<td>• Fewer cases, or case reports</td>
</tr>
<tr>
<td></td>
<td>• Conflicting evidence with the weight of evidence supporting the recommendation</td>
</tr>
<tr>
<td>C</td>
<td>Expert consensus or clinical experience</td>
</tr>
</tbody>
</table>

*Diabetes Care 2003;26(suppl 1):S1.
†Either all patients died before therapy and at least some survived with therapy or some patients died without therapy and none died with therapy. Example: use of insulin in the treatment of diabetic ketoacidosis

REFERENCES

Diabetic ketoacidosis: bolus versus no bolus.


